

# The gliptin: one type of potential drug for the treatment of fibrotic diseases

Zhongyao Liang<sup>1,\*</sup>

<sup>1,\*</sup>: West China clinical college, Sichuan University

## Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions.

## Abstract

Fibrosis is a common terminal state of many chronic diseases and there are few effective treatments at present. The gliptin is a class of DPP4 inhibitors used in the treatment of type 2 diabetes. At present, many studies show that it may have the effect of inhibiting fibrosis. In order to explore the role of the gliptin in different fibrotic diseases, we searched the related literature about the fibrotic diseases and the gliptin. In our review, we found that the gliptin can inhibit the fibrotic process through a variety of mechanisms. The evidence for the inhibition of atherosclerosis by the gliptin is strong. For pulmonary, renal and cardiac fibrosis, more clinical studies are needed to support it. However, there is no benefit in the treatment of liver fibrosis with the gliptin. To sum up, it is true that the gliptin has the broad-spectrum anti-fibrotic effects.

## Key Word

Gliptins

Fibrosis

DPP4

Atherosclerosis

Linagliptin

Sitagliptin

## Introduction

Fibrotic disease is a general term for the process of chronic diseases caused by improper repair of connective tissue after the tissue damage. Tissue damage can occur in various parts of the body, which also suggests that fibrosis can occur in almost every tissue and organ system. There are two kinds of fibrotic diseases: One is the fibrotic disease confined to specific organs, such as liver fibrosis, kidney fibrosis, myocardial fibrosis, skin fibrosis and so on. The other is the fibrotic disease involving multiple system organs, such as systemic sclerosis, chronic graft vs host disease, etc.

In the pathogenesis of fibrosis, the core element is that fibroblasts are stimulated by various factors to transform into myofibroblasts and secrete excessive extracellular matrix.<sup>1,2</sup> As the T cell surface antigen, DPP4 is a serine protease on the surface of cell membrane which is widely distributed on various cell surfaces including fibroblasts.<sup>3</sup> DPP4 is mainly related to immune regulation, cytokine digestion and T cell activation. Many studies have shown that DPP4 positive fibroblasts are the main effector cells that secrete extracellular matrix and participate in the process of fibrosis, so DPP4 may be a potential target for the treatment of fibrotic diseases.<sup>4-10</sup>

At present, the DPP4 inhibitor that have been used in clinic is the gliptin, which are widely used in the treatment of type II diabetes. The gliptin reduces the inactivation of GLP-1 by inhibiting DPP4 activity and increased levels of GLP-1 enhance insulin secretion. The gliptin is a kind of safe, effective and convenient

antihyperglycemic drug because of no weight gain and few hypoglycemic events.

According to the mechanism of action, the existing gliptins can be divided into two categories and their relevant information is described in Table 1. The existing studies have found that the gliptin has an inhibitory effect on a variety of fibrotic diseases. This study aims to summarize and explore the anti-fibrotic effects of the gliptin by searching the literature related to the gliptin used in the fibrosis. (Fig 1)

### **Pulmonary fibrosis**

Pulmonary fibrosis is the end-stage change of many lung diseases, characterized by the proliferation of fibroblasts, the accumulation of extracellular matrix and the destruction of tissue structure. A variety of irritant factors can cause lung inflammation and damage, and further cause pulmonary fibrosis. Idiopathic fibrosis is one of the most important diseases in fibrosis which etiology is unknown and there is no effective treatment at present.

DPP4 is widely distributed on various cell surfaces of the lung, which is considered to be an important antigen deeply involved in lung immune and inflammatory response.<sup>11,12</sup> It has been found that the expression of DPP4 in bronchial epithelial cells increases significantly after lung injury.<sup>13</sup> Inhibition of DPP4 activity can prevent inflammation and vascular injury.<sup>14</sup>

Uncontrolled inflammatory response is also an important cause of initiating pulmonary fibrosis. In the pathogenesis of pulmonary fibrosis, not only the involvement of fibrosis-related TGF- $\beta$  pathway, but also the epithelial-mesenchymal transition plays an important role. Epithelial-mesenchymal transition is a process in which epithelial cells are transformed into fibroblasts and the abundant epithelial cells in the lung become an important source of fibroblasts in the process of pulmonary fibrosis.<sup>15</sup>

At present, most of the researches on the relationship between the gliptin and pulmonary fibrosis are basic researches. Among them, the studies of vildagliptin and sitagliptin accounts for the highest proportion. Vildagliptin and sitagliptin were found to inhibit pulmonary fibrosis in mice induced by injection of lipopolysaccharide or bleomycin.<sup>15, 17</sup> In the case of alogliptin, it is currently found that it may not have a mitigating effect on pulmonary fibrosis.<sup>21</sup> At present, there are few clinical studies on the relationship between gliptin and pulmonary fibrosis. Vildagliptin and sitagliptin are the most likely potential drugs to treat pulmonary fibrosis.<sup>17</sup>

The different gliptin inhibits pulmonary fibrosis through different mechanisms of action. The effect of sitagliptin is mainly through the regulation of TGF- $\beta$  signaling pathway.<sup>16, 18, 20</sup> It inhibits pulmonary fibrosis by inhibiting the TGF- $\beta$  pathway to reduce the inflammatory response and the degree of activity of fibroblasts. Vildagliptin can further reduce extracellular matrix deposition by inhibiting epithelial-to-mesenchymal transition, thus alleviating the process of pulmonary fibrosis. One of the most important findings in these studies is that the antifibrotic effect of gliptin is also found in animal models without diabetes, showing that gliptin has a direct inhibitory effect on fibrosis partly independent of the regulation of diabetes. Of course, given that diabetes may be one of the risk factors for pulmonary fibrosis,<sup>22</sup> the gliptin may suppress pulmonary fibrosis of diabetic rats in part by inhibiting diabetes.

It is worth noting that asthma is also a type of lung disease that can cause pulmonary fibrosis. It has been shown in the literature that saxagliptin and sitagliptin can inhibit asthma by inhibiting the inflammatory response in the airway and the production of related cytokines.<sup>16,19</sup>

In general, the inhibitory effect of gliptin on pulmonary fibrosis is mainly reflected in basic research and more clinical studies are needed to prove it. (Table 2)

### **Liver fibrosis**

Liver fibrosis is a common terminal state of many liver diseases. Many kinds of injury factors lead to liver over-repair and eventually lead to liver fibrosis.<sup>23,24,25</sup> Hepatic stellate cell (HSC) is a unique and

important factor in the development of hepatic fibrosis. Hepatic stellate cell are the mesenchymal cell of the liver, which are in a resting state under the normal condition. In that process of liver fibrosis, the hepatic stellate cell are activated by various factors to transform into myofibroblasts, which participate in the synthesis of extracellular matrix and structure remodeling, and finally lead to the formation of liver fibrosis.<sup>26,27,28</sup> Nonalcoholic fatty liver disease (NAFLD) is an important cause of liver fibrosis, which affects more than 70% of patients with type-2 diabetes.<sup>29</sup> Currently, there is a lack of drug that can reverse liver fibrosis.

At present, there are many studies on the relationship between the gliptin and liver fibrosis, but the conclusions of basic research and clinical research are obviously different or even contrary. In that basic study, liver fibrosis is induced in mice by carbon tetrachloride, pig serum or streptozotocin, regardless of whether the mice also have diabetes or non-alcoholic liver disease, the gliptins are able to inhibit liver fibrosis in mice.<sup>30,31,33-36,41,43-46,48</sup> The combination of gliptin with pioglitazone [31], oleanolic acid (TGR5 agonist),<sup>32, 43</sup> Empagliflozin (an SGLT2 inhibitor),<sup>33</sup> Canagliflozin<sup>37</sup> or Silymarin<sup>44</sup> can produce a synergistic effect.

But the results of the clinical studies are far from satisfactory. Current clinical studies have mainly been associated with sitagliptin, but most<sup>40, 41, 47</sup> have shown that sitagliptin does not inhibit liver fibrosis and non-steatoalcoholic hepatitis in patients with or without diabetes. There is even a literature<sup>39</sup> that suggests that gliptins increase the incidence of hepatic decompensation in cirrhotic patients.

The anti-fibrotic effect of the gliptin is mainly through inhibiting hepatic stellate cells, inflammatory reaction, TGF- $\beta$  pathway and NF- $\kappa$ B pathway. Secondly, some studies have shown that GLP-1 can inhibit liver fibrosis and inflammatory reaction, thus playing a protective role in liver. GLP-1 receptor agonists may be potential drugs to inhibit liver fibrosis.<sup>49,50</sup> Therefore, the inhibition of liver fibrosis by the gliptin may be partly mediated by the effect on GLP-1.

Given the reliability of the clinical evidence, we believe that the gliptin may not be able to inhibit liver fibrosis in patients. (Table 2)

### **Renal fibrosis**

Renal fibrosis is the end stage of many renal diseases, which is mainly manifested by the reduction of intrinsic cells, the deposition of extracellular matrix and the inevitable renal failure. When the kidney is stimulated by a variety of injury factors, a series of inflammatory response factors can transform the intrinsic cells and fibroblasts of the kidney into myofibroblasts which lead to the excessive secretion of collagen and other extracellular matrix. TGF- $\beta$  pathway and epithelial-mesenchymal transition are the main processes involved in renal fibrosis.

In all organ, the expression level of DPP4 is the highest in the kidney. It is widely expressed on the cell membrane of podocytes, mesangial cells, proximal tubule cells and deeply participate in the process of the tissue structure remodeling and epithelial-mesenchymal transformation of kidney.<sup>70-73</sup> Crescent is an important marker of nephritis formation. It has been found that DPP4 is highly expressed in the crescents in different nephritis models.<sup>52</sup>

Most of the current studies on the role of gliptins in renal fibrosis are basic studies, with the largest number of studies on sitagliptin and linagliptin. Renal fibrosis is induced in mice by injection of streptomycin<sup>57, 61, 62, 64, 67</sup>, unilateral ureteral ligation<sup>54, 65, 68</sup> and other methods<sup>54-56, 58-60, 63, 65, 66, 68, 69</sup>. It is then found that the gliptin can inhibit the process of renal fibrosis or renal interstitial fibrosis and this inhibition is greater than that of telmisartan<sup>59, 61</sup>.

The inhibitory effect of gliptin on the progression of renal fibrosis is mainly through the inhibition of inflammatory injury, TGF- $\beta$  pathway and epithelial-mesenchymal transition. Diabetes is one of the

important factors causing renal injury and is closely related to the occurrence of renal fibrosis<sup>74</sup>. By inhibiting the progression of diabetes, the gliptin inevitably slow the progression of renal fibrosis partly dependent on the regulation of GLP-1<sup>66</sup>. However, the inhibitory effect of the gliptin on renal fibrosis can be independent of the regulation of blood glucose<sup>54, 55, 56, 58, 59, 60, 66, 69</sup>. Linagliptin inhibits the formation of the crescent and inhibits the process of renal fibrosis by modulating the immune response<sup>52</sup>.

On the whole, sitagliptin and linagliptin may be effective enough to inhibit renal fibrosis, but more clinical studies are needed to prove it.(Table 2)

### **Cardiac fibrosis**

Insufficient blood supply of coronary artery leads to repeated ischemia and anoxia of myocardial cells, which will eventually lead to myocardial fibrosis. Myocardial fibrosis can lead to decreased cardiac compliance, which in turn causes ventricular diastolic and systolic dysfunction, and even arrhythmia.

Normally, fibroblasts located in the interstitial and perivascular spaces secrete a small amount of collagen for maintaining the basic mechanical strength and cytoskeleton of the cardiovascular tissue. Myocardial fibrosis occurs when collagen accumulation is caused by excessive secretion or decreased degradation of collagen.

The unique and important pathogenesis of cardiac fibrosis is the mechanism of angiotensin II . Angiotensin II increases and combines with its receptor, which promotes the transformation of myofibroblasts and the activation of TGF-  $\beta$  1 pathway and finally accelerates cardiac fibrosis<sup>75, 99, 100</sup>.

GLP-1 receptors are widely distributed in the cardiovascular system including cardiomyocytes and endothelial cells and GLP-1 is thought to have protective effects on heart injury, which is mainly mediated by mechanisms such as PIK3, AKT and p38<sup>101-104</sup>. The protective effect of GLP - 1 on the heart naturally has some inhibitory effect on myocardial fibrosis.

At present, most of the studies on the relationship between the gliptin and cardiac fibrosis are basic studies. Studies have shown that linagliptin<sup>77-82</sup>, sitagliptin<sup>91-98</sup>, saxagliptin<sup>83-85</sup> and vildagliptin<sup>86-90</sup> can inhibit cardiac fibrosis. The inhibitory effect of gliptin on myocardial fibrosis seems to be partly independent of blood glucose regulation. The inhibitory effect of vildagliptin on cardiac fibrosis is similar to that of enalapril<sup>88, 89</sup>.

Firstly, the inhibition of cardiac fibrosis by gliptin acts by inhibiting the initial factors. Gliptin can inhibit the production of reactive oxygen species<sup>76, 77, 81, 92, 95</sup> and inflammatory factors<sup>78, 92</sup>, thereby reducing the stress damage caused by ischemia and hypoxia and finally slowing down the occurrence of cardiac fibrosis. Secondly, the effect of angiotensin II on the acceleration of cardiac fibrosis is inhibited by the gliptin<sup>80, 82, 85</sup>. Finally, the gliptin can increase the level of GLP-1 and exert the cardioprotective effect through the downstream pathways of AKT, PIK3 and p38, and finally inhibit the fibrosis of the heart<sup>82, 87, 88, 91, 96, 97</sup>.(Table 2)

### **Atherosclerosis**

The main characteristics of vascular fibrosis are excessive deposition of extracellular matrix, hardening of vascular wall and thickening of vascular wall. Vascular fibrosis can cause a range of clinical diseases, the most important of which is atherosclerosis<sup>124 - 126</sup>. Under the action of a variety of stimulating factors, smooth muscle cells, macrophages, T cells and endothelial cells participate in the process of arteriosclerosis, resulting in excessive collagen and relatively lack of elastin in the vascular wall<sup>127-129</sup>.

The main pathological mechanisms involved in atherosclerosis are abnormal activation of the TGF- $\beta$  pathway, activation of the RAAS system and increased levels of oxidative damage, which ultimately contribute to the development of vascular fibrous hyperplasia<sup>130</sup>.

At present, there are many basic and clinical studies on atherosclerosis and the gliptin.

Basic studies have shown that the gliptin can inhibit atherosclerosis in diabetic mice<sup>105, 106, 108, 111, 120</sup> and non-diabetic mice<sup>109, 113, 114, 116, 117</sup>. Clinical studies have shown that the gliptin can prevent the occurrence of atherosclerosis in patients with diabetes<sup>107, 115, 118, 119, 121-123</sup>, which is rarely reported in non-diabetic patients. In the prevention of atherosclerosis, the combination of gliptin and insulin or metformin has a synergistic effect<sup>118, 121, 123</sup>. For patients who have already developed atherosclerotic plaques, the gliptin may not have the effect of reducing the plaque<sup>122</sup>.

This inhibition is mediated mainly by two important pathways. The first is the GLP - 1 pathway, in which a statin can up-regulate GLP - 1 in the blood. On the one hand, GLP-1 has a direct protective effect on blood vessels and can directly inhibit inflammation of blood vessels<sup>131</sup>. On the other hand, GLP-1 can slow down the progression of diabetes, thus indirectly slowing down the vascular damage caused by diabetes<sup>132</sup>.

Next is the inhibitory effect of the gliptin by promoting the polarization of macrophage. Macrophage is an important subpopulation of cell involved in a variety of inflammatory responses<sup>133</sup>. First of all, one of the most important initiation factors in the development of atherosclerosis is the occurrence of inflammatory damage. Macrophage is divided into M1 and M2<sup>134</sup>, the former promotes inflammatory reaction, the latter inhibits inflammatory reaction. Up-regulation of the proportion of M1-type macrophages can promote the occurrence of vascular fibrosis and up-regulation of the proportion of M2 type macrophages could inhibit the occurrence of atherosclerosis<sup>135, 136</sup>. Secondly, macrophage is involved in the formation of foam cells, an important event in the early stages of atherosclerosis. DPP4 is an important molecule involved in the immune response and DPP4 inhibitors are found to up-regulate the proportion of M2-type macrophages in the liver and abdominal cavity of mice<sup>137</sup>. The studies we collected suggest that the gliptin can inhibit the development of atherosclerosis by increasing the proportion of M2-type macrophages and inhibiting macrophage-related functions<sup>109, 124, 127, 120</sup>.

On the whole, sitagliptin may be the best drug to inhibit atherosclerosis among the gliptins.(Table 2)

### **Other fibrosis**

In addition to the common fibrotic diseases, there is currently a small amount of researches on the use of the gliptin for other fibrotic diseases.

Basic studies have shown that the gliptin inhibits catheter-related peritoneal fibrosis after dialysis<sup>138</sup>, ovarian fibrosis<sup>139</sup>, fatty fibrosis<sup>144</sup>, hypertrophic scars<sup>143</sup> and systemic sclerosis<sup>142</sup>. Some clinical studies have shown that the gliptin can also reduce the occurrence of cystic fibrosis<sup>140</sup>, keloids<sup>146</sup> and chronic graft vs host disease<sup>145</sup>. The major pathophysiological processes of chronic graft vs host disease also involve vascular fibrosis.

The inhibitory effect of the gliptin on these fibrotic diseases is mainly through inhibiting the immune function of DPP4 and TGF-  $\beta$  pathway. The risk of hypoglycaemia associated with the use of gliptin is low. Therefore, the gliptin may be effective in the treatment of these fibrotic diseases alone or in combination<sup>147-149</sup> with other drugs. Although there are few studies at present, it provides some enlightenment for the further clinical study on the application of gliptin in the treatment of fibrotic diseases.(Table 2)

### **The most promising drug candidates**

Based on our statistical results, we found that sitagliptin and linagliptin are the most promising gliptins in terms of anti-fibrosis.

There is a lack of literature on licagliptin in pulmonary fibrosis, but it has been shown to be effective in inhibiting other types of fibrosis except liver fibrosis. In addition, linagliptin has the unique anti-fibrotic mechanism and advantage. DPP4, as a kind of important cell surface marker, can promote the activation of TGF-  $\beta$  pathway and its downstream epithelial-stromal transformation by binding with integrin  $\beta$ , thus

accelerating the development of fibrosis<sup>24</sup>. Linagliptin can inhibit the activation of TGF- $\beta$  pathway by inhibiting the integrin  $\beta$  pathway, which is the unique mechanism of linagliptin<sup>65</sup>. Moreover, linagliptin is the only type of gliptin that does not need to be adjusted according to the liver and kidney function of the patient. Therefore, we consider it an important candidate for anti-fibrosis drug.

Sitagliptin is also an important drug candidate. Not only does sitagliptin account for the largest proportion of the literature, but sitagliptin can inhibit all types of fibrosis except liver fibrosis. Moreover, more than 80% of the clinical research literature is about sitagliptin, indicating that it has the greatest anti-fibrotic potential.(Fig 2)

## Conclusion

In general, that evidence for the inhibition of a variety of fibrotic disease, especially in the inhibition of atherosclerosis, is strong. In lung, kidney and heart fibrosis, more clinical studies are needed to prove it. It is important to note that the gliptin may have no significant effect on inhibiting liver fibrosis.

The inhibition of fibrotic disease by statin drugs works through a variety of mechanisms, such as TGF- $\beta$ , ECM, antioxidant damage, GLP-1 and so on. The anti-fibrotic drugs currently in development work mainly through seven mechanisms<sup>150</sup> and five of them are related to the mechanism of action of the gliptin. Not only that, the antifibrotic range of the gliptin encompasses almost all of the drugs currently in the R & D phase.<sup>150</sup> These suggest that the role of the gliptin in the field of anti-fibrotic therapy cannot be underestimated.(Fig 3)

Basic researches suggest that the inhibitory effect of the gliptin on the fibrotic diseases can be independent of diabetes. Our study identified sitagliptin and linagliptin were the most promising anti-fibrotic drugs. However, most of the clinical studies on the relationship between the gliptin and fibrotic diseases involve patients with diabetes mellitus, which leads to the need for more clinical evidences or trials to show that the gliptin also has an inhibitory effect on fibrotic disease in non-diabetic patients.

**Table 1 Classification of the gliptins**

	Peptide Mimetic	Non-Peptide Mimetic
<b>Representative Drugs</b>	Sitagliptin,Saxagliptin,Vildagliptin	Alogliptin,Linagliptin
<b>the Mechanism of Action</b>	Mimic the DPP4 enzyme substrate structure and bind to the DPP4 site competitively.	Specifically binding to the DPP4 active site, thereby inactivating DPP4.
<b>Characteristics of Function</b>	Low selectivity, non-covalent binding and low specificity.	High selectivity, high specificity, and thus long-lasting drug effect without multiple administration

**Table 2 Literatures on the study of gliptins in fibrotic diseases**

Pulmonary Fibrosis						
	Object	Result	Mechanism	Size*	Drug	Diabetic or HG-treatment
<i>Manar G. Helal,2019[19]</i>	Rats with acute allergic asthma	Marked antiasthmatic effect	NF- $\kappa$ B	10	Sa	N
<i>Toshio Suzuki,2017[15]</i>	Rats with lung	Ameliorate pulmonary fibrosis	EMT, DPP4	5	Vi	N

injury						
<i>Yang Liu,2020[17]</i>	Rats with idiopathic pulmonary fibrosis	A promising therapeutic candidate for idiopathic pulmonary fibrosis.	DPP4,ECM	9	Vi	N
<i>Xiuwu Liu,2020[18]</i>	TGF $\beta$ -activated human lung fibroblasts	Inhibits fibroblasts	TGF- $\beta$	$\geq 3$	Si	N
<i>Manar A. Nader,2015[16]</i>	Mice with chronic asthma	Relieve asthma	Inflammation,TGF- $\beta$ ,ROS	10	Si	N
<i>Jian Xu,2018[20]</i>	Rats with pulmonary hypertension	Inhibit pulmonary arterial adventitia fibrosis	EMT,inflammation	8	Si	N
<i>Shota Hodono,2018[21]</i>	Rats with pulmonary fibrosis	Don't ameliorate pulmonary fibrosis after lung injury	-----	7	AI	N
Liver Fibrosis						
<i>Hanyan Zhang,2019[30]</i>	Rats with CCl <sub>4</sub> -induced liver fibrosis	Alleviate liver fibrosis	Stellate cell	7	AI	N
<i>Yuichiro Amano,2018[31]</i>	Rats with modified choline-deficient L-amino acid-defined diet	Combination therapy (pioglitazone+AI) can inhibit nonalcoholic fatty liver disease and its fibrotic process	-----	16	AI	Y
<i>Daisuke Kaya,2019[32]</i>	Diabetic rats with liver fibrosis	Inhibit liver fibrosis. A synergistic effect when used in combination with oleanolic acid( TGR5 agonist)	Stellate cell	10	An	Y
<i>Teruo Jojima,2016[33]</i>	Diabetic rats with non-alcoholic steatohepatitis	Inhibit liver fibrosis. A synergistic effect when used in combination with Empagliflozin (an SGLT2 inhibitor)	-----	6	Li	Y
<i>Thomas Klein,2014[34]</i>	Rats with non-alcoholic steatohepatitis	Inhibit liver fibrosis.	DPP4,macrophage, inflammation	7	Li	N
<i>Yara M. Aboulmagd,2020[35]</i>	Obesity rats with diabetes	Inhibit liver fibrosis.	Inflammation,ECM	6	Li	Y
<i>Xiaoyu Wang,2016[36]</i>	Rats with non-alcoholic steatohepatitis	Mild direct anti-fibrotic properties	ROS,macrophage,inflammation	7	Si, Li	N
<i>Takahiro Ozutsum,2020[37]</i>	Rats with liver fibrosis	Inhibit liver fibrosis. A synergistic effect when used in combination with Canagliflozin	TGF- $\beta$ ,ECM	10	Te	N
<i>Rania Khalil,2020[38]</i>	Rats with CCl <sub>4</sub> -induced liver fibrosis	A hopeful candidate for adjuvant treatment of liver fibrosis.	ERK1/2, p38 $\alpha$ ,NF- $\kappa$ B	15	Vi	N

<i>Fu- Shun Yen,2021[39]</i>	Diabetic patients with liver cirrhosis	Accelerate cirrhosis Decompensation.	-----	2828	Gliptins	Y
<i>Jeffrey Cui,2016[40]</i>	Prediabetic patients with nonalcoholic fatty liver disease	Safe but not better than placebo in reducing liver fibrosis in patients.	-----	50	Si	Y
<i>Kosuke Kaji,2012[41]</i>	Pigs with serum-induced liver fibrosis	May represent a potential new therapeutic strategy against liver fibrosis	ERK1/2, p38,TGF- $\beta$ , stellate cell,ECM	10	Si	N
<i>Mark M. Smits,2016[42]</i>	Patients with hepatic steatosis and fibrosis	Do not reduce hepatic steatosis or fibrosis in type 2 diabetes patients.	-----	52	Si	Y
<i>Naotaka Shimozato,2019[43]</i>	Nonalcoholic fatty liver disease in rats with liver fibrosis	Combination therapy (OCA+Si) may be more beneficial for reducing atherosclerosis	stellate cell	50	Si	N
<i>Samia Salem Sokar,2017[44]</i>	Rats with CCl <sub>4</sub> -induced liver fibrosis	Inhibit liver fibrosis. A synergistic effect when used in combination with Silymarin	TGF- $\beta$ ,ROS,inflammatio n	8	Si	N
<i>Shahinul Alam,2018[45]</i>	Patients with nonalcoholic fatty liver disease	Ameliorates steatosis and ballooning, irrespective of diabetes.	-----	40	Si	N
<i>TAKUMI ONOYAMA,2015[46]</i>	Rats with non-alcoholic steatohepatitis	Attenuate hepatic fibrosis	Inflammation,ROS,s tellate cell	10	Si	Y
<i>Tisha R Joy,2017[47]</i>	Patients with non-alcoholic steatohepatitis	Does not improve fibrosis score or NAS after 24 weeks of therapy.	-----	6	Si	N
<i>Yun-A. Jung,2014[48]</i>	Rats with steatohepatitis	Decreased liver fibrosis.	-----	5	Si	N
Kidney Fibrosis						
<i>Takahiro Uchida,2017[54]</i>	Rats with acute renal injury	Alleviate renal fibrosis	Macrophage,inflam mation,TGF- $\beta$ .	9	Al	N
<i>Jung Beom Seo,2018[55]</i>	Rats with acute renal injury	Alleviate renal fibrosis	Inflammation(NLRP 3), TGF- $\beta$	6	Ge	N
<i>Anna-Lena Mayer,2016[56]</i>	Rats with nephritis	Alleviate renal fibrosis	Macrophage,inflam mation	11	Li	N
<i>Keizo Kanasaki,2014[57]</i>	Diabetic-2 rats with renal fibrosis	Alleviate renal fibrosis	EMT	6	Li	Y
<i>Muralikrishna,2015[58]</i>	Rats	Inhibition expression of fibronectin	TGF- $\beta$	9	Li	N
<i>Oleg Tsuprykov,2016[59]</i>	Rats with chronic renal disease	Ameliorate interstitial fibrosis(no less than that of telmisartan). No	-----	14	Li	N



obvious effect on perivascular fibrosis of kidney						
Masako Uchii,2016[60]	Hypertensive rats	Reduce renal fibrosis caused by renal injury	Inflammation,DPP4	10	Sa	N
Muralikrishna,2016[61]	Diabetic-1 rats	Alleviate renal fibrosis(better than telmisartan)	TGF- $\beta$	8	Sa	Y
Wei Jing Liu,2011[62]	Diabetic-2 rats	Delay glomerular and tubulointerstitial fibrosis	TGF- $\beta$ ,DPP4	8	Vi	Y
Cristina Mega,2011[63]	Diabetic-2 rats	Ameliorate interstitial fibrosis,long-term use of lower doses is better	—————	8	Si	Y
Dongdong Wang,2018[64]	Diabetic-2 rats	Inhibit progressive renal fibrosis.	TGF- $\beta$ ,ECM	8	Si	Y
Esther Civantos,2017[65]	Diabetic-2 rats	Ameliorate interstitial fibrosis	ROS	6	Si	Y
Jian Xu,2018[66]	Kidney-damaged rats	Alleviate renal fibrosis(same as liraglutide(GLP-1R agonist))	GLP-1	8	Si	N
LUXIN LI,2019[67]	Diabetic-1 rats	Significantly inhibit renal fibrosis.	TGF- $\beta$	7	Si	Y
Md. Ashraful Alam,2015[68]	Diabetic nephropathy and renal hypertension rats	Prevent renal fibrosis	ROS	6	Si	Y
Chor Ho Jo,2018[69]	Rats with hypertension and renal injury	Ameliorate interstitial fibrosis	Inflammation(NLRP 3)	5,5	Si,Li	N
Cardiac Fibrosis						
Xiaowei Zhang,2018[76]	Rabbits	Alleviate interstitial fibrosis	ROS	10	Al	N
Annayya R. Aroor,2013[77]	Obesity rats	Alleviate cardiac fibrosis	ROS	11	Li	N
Annayya R. Aroor,2017[78]	Obesity rats	Inhibit the production of collagen and cardiac fibrosis	Inflammation	10	Li	N
Hiroyuki Hirakawa,2015[79]	Autoimmune myocarditis rats	Remarkably suppressed cardiac fibrosis	Inflammation	19	Li	N
Li-Hui Zhang,2015[80]	AngII-infused rats	Inhibit cardiac fibrosis	Ang II	6	Li	N
Tazuru Igarashi,2018[81]	Atrial fibrillation dogs	Inhibit the myocardial fibrosis	ROS	8	Li	N
Xian-wei WANG,2016[82]	Mouse cardiac fibroblasts	Inhibit collagen formation	ERK/NF- $\kappa$ B pathway.	5	Li	Y
Jessica A. Hiemstra,2016[83]	Heart failure rats	Inhibit collagen formation	————	8	Sa	N
Junichi Ikeda,2016[84]	Myocardial fibrosis mouse	Suppress myocardial fibrosis	DPP4	15	Sa	N
Scott M. Brown,2017[85]	AngII-infused rats	Attenuat periarterial fibrosis	Ang II	6	Sa	N
Ahmed A.M,2019[86]	Diabetic-2 rats	May not have a positive impact on fibrotic changes.	————	16	Vi	Y
Ayako Takahashi,2013[87]	Heart failure rats	Palliate cardiac fibrosis	GLP-1	10	Vi	N
Nattayaporn Apaijai,2016[88]	Diabetic-2 rats	Inhibit cardiac fibrosis (better than enalapril)	ERK1/2	6	Vi	Y

<i>Tharnwimol Inthachai,2015[89]</i>	Rats with cardiac infarction	Inhibit cardiac fibrosis ( same as enalapril)	-----	6	Vi	N
<i>Toru Miyoshi,2014[90]</i>	Isoproterenol-treat ed rats	Attenuat the hypertrophy and perivascular fibrosis	-----	20	Vi	N
<i>Belén Picatoste,2013[91]</i>	Diabetic-2 rats	Alleviate cardiac fibrosis	GLP-1	10	Si	Y
<i>Grazia Esposito,2016[92]</i>	Hypertension rats	Alleviate cardiac fibrosis	NOS, ROS	35	Si	N
<i>Kim Alexander Connelly,2012[93]</i>	Diabetic-1 rats	Inhibit collagen formation	-----	6	Si	Y
<i>M. Lenski,2011[94]</i>	Diabetic-2 rats	Prevented myocardial fibrosis	TGF- $\beta$	7	Si	Y
<i>Md. Ashraf Alam,2015[95]</i>	Diabetic nephropathy and hypertension rats	Prevented cardiac fibrosis	ROS	6	Si	Y
<i>Nouf M Al-Rasheed,2016[96]</i>	Diabetic-2 rats	Attenuates cardiomyopathy and fibrosis	JAK/STAT	8	Si	Y
<i>Nouf T. Al-Damry,2018[97]</i>	Diabetic-2 rats with cardiomyopathy	Alleviate cardiac fibrosis	LKB-1/AMPK/Akt, apoptosis	8	Si	Y
<i>Yu-Sheng Liu,2015[98]</i>	Diabetic-2 rats	Alleviate cardiac fibrosis	-----	20	Si	Y
<b>Atherosclerosis</b>						
<i>Michishige Terasaki,2017[105]</i>	ApoE-/- rats(diabetic)	Combination therapy (SGLT2i+Al)imay be more beneficial for reducing atherosclerosis	-----	8	Al	Y
<i>Nga N. Ta, MS,2011[106]</i>	ApoE-/- rats(diabetic)	Inhibit atherosclerosis	Monocyte,Inflamma tion	8	Al	Y
<i>Tormoya Mita,2016[107]</i>	Patients with atherosclerosis	Inhibit atherosclerosis	-----	172	Al	Y
<i>Zubair Shah,2011[108]</i>	LDLR-/- rats fed with a high fat diet	Inhibit atherosclerosis	Monocyte	15	Al	Y
<i>Tsutomu Hirano,2016[109]</i>	Cholesterol-fed rabbit	Can substantially suppress plaque formation in coronary arteries	Inflammation,Macr ophage	16	An	N
<i>Hwan-Jin Hwang,2015[110]</i>	Human umbilical vein endothelial cells and THP-1 cells.	Inhibit atherosclerosis	NF- $\kappa$ B , JNK,	3	Ge	N
<i>Camila Manrique,2016[111]</i>	Rats with vascular abnormalities	Inhibit atherosclerosis	-----	10	Li	Y
<i>Haoran Wang,2020[112]</i>	Oxidized LDL-Induced THP-1 Macrophage Foam Cell	Prevent foam cell formation in vitro	-----	5	Li	N
<i>Hotimah Masdan Salim, 2016[113]</i>	ApoE-/- rats(no diabetic)	Inhibit atherosclerosis	ROS,DPP4, Endothelial cells	16	Li	N
<i>Shuhei Nishida,2020[114]</i>	High fat diet	Inhibit atherosclerosis	DPP4,Macrophage	21	Li	Y

	(HFD)-fed ApoE <sup>-/-</sup> mice					
<i>Stefanie A. de Boer,2017[115]</i>	Early diabetes patients with atherosclerosis	Inhibit arterial stiffness.	-----	22	Li	Y
<i>Kunduziayi Aini,2019[116]</i>	ApoE <sup>-/-</sup> rats(no diabetic)	Inhibit atherosclerosis	GLP-1	11	Vi	N
<i>Michishige Terasaki,2012[117]</i>	ApoE <sup>-/-</sup> rats(no diabetic)	Significantly suppressed total aortic atherosclerotic lesions	Macrophage	21	Vi	N
<i>Rehab Werida,2020[118]</i>	Patients with type II diabetes mellitus	Combination therapy (DMBG+Vi) may be more beneficial for reducing atherosclerosis	-----	40	Vi	Y
<i>Bo Li,2020[119]</i>	Diabetic patients with coronary artery sclerosis	Inhibit atherosclerosis significantly.	-----	74	Si	Y
<i>F.Vittone,2012[120]</i>	ApoE <sup>-/-</sup> rats(diabetic)	Stabilise arteriosclerotic lesions	GLP-1, Monocyte, M acrophage, MMP	10	Si	Y
<i>Tomoya Mita,2017[121]</i>	Patients with type II diabetes	Combination therapy (insulin+Si) may be more beneficial for reducing atherosclerosis	-----	137	Si	Y
<i>Tsuyoshi Nozue,2016[122]</i>	Diabetes patients undergone coronary intervention	Do not significantly reduce coronary plaque volume.	-----	28	Si	Y
<i>Xiaojie Liu,2017[123]</i>	Patients with type II diabetes	Combination therapy (DMBG+Si) may be more beneficial for reducing atherosclerosis	-----	44	Si	Y
<b>Other Fibrosis</b>						
<i>Takuo Nagai,2016[138]</i>	Rats with peritoneal fibrosis	Ameliorate peritoneal fibrosis.	TGF- $\beta$ , GLP-1	6	Li	N
<i>Fang Wang,2019[139]</i>	Rats with ovarian fibrosis	Delays the process of ovarian fibrosis	TGF- $\beta$	10	Si	Y
<i>Samuel T. Olatunbosun,2021[140]</i>	Patients with cystic fibrosis	Delay the progress of cystic fibrosis	Be related to diabetes control, not a direct effect	3	Si	Y
<i>Yi-Chen Li,2021[141]</i>	Patients with Peritoneal dialysis	Reduce the incidence of fibrosis after peritoneal dialysis	EMT	19828	Si	Y
<i>Alina Soare,2020[142]</i>	Dermal fibroblasts from human systemic sclerosis	Inhibit fibroblasts	TGF- $\beta$	6	Si, Vi	N

<i>Yan Li,2019[143]</i>	Fibroblasts derived from hypertrophic scar	inhibits high glucose-induced transdifferentiation of hypertrophic scar-derived fibroblasts to myofibroblasts	IGF/Akt/mTOR	6	Li	Y
<i>Ana Patricia,2018[144]</i>	Obese rats	Prevents fibrosis formation in adipose tissue.	-----	10	Vi	Y
<i>Sherif S. Farag,2021[145]</i>	Patients undergone allogeneic hematopoietic stem cell transplantation	Combination therapy (tacrolimus/sirolimus+Si) resulted in a low incidence of grade II to IV acute GVHD	DPP4	36	Si	N
<i>Hirotsugu Suwanai,2020[146]</i>	Sternotomy patients	Suppress the onset of hypertrophic scars or keloids after surgery in humans	-----	5430	Gliptins	Y

Li:Linagliptin; An: Anagliptin; Te:Teneligliptin;Sa:Saxagliptin; Vi:Vildagliptin; Si:Sitagliptin; Al:Alogliptin; Ge:Gemigliptin;Y:Yes; N:No; HG: High glucose ; NAS:NAFLD Activity Score; ROS:reactive oxygen species;Size\*:Sample size of experimental group;ApoE:apolipoprotein E gene; LDLR: Low-Density Lipoprotein Receptor

The red portion represents the study which is the clinical literature or in which result doesn't suggest gliptins can inhibit the fibrosis.

**Figure 1: the Roadmap of the research**






Figure 2: Statistical diagram of the distribution of the researches



**Figure 3: Statistical diagram of anti-fibrotic mechanisms of gliptins**



## Reference

1. Gabbiani, G. The myofibroblast in wound healing and fibrocontractive diseases. *J. Pathol.* 200, 500–503 (2003).
2. Kalluri, R., Zeisberg, M. Fibroblasts in cancer. *Nat. Rev. Cancer* 6, 392–401 (2006).
3. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function [J]. *Trends Immunol*, 2008,29(6):295-301.
4. Rinkevich Y, Walmsley GG, Hu MS, et al. Skin fibrosis. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential [J]. *Science*, 2015,348(6232):aaa2151.

5. CD26 Identifies a Subpopulation of Fibroblasts that Produce the Majority of Collagen during Wound Healing in Human Skin  
Journal of Investigative Dermatology 2020, doi:10.1016/j.jid.2020.04.010
6. Xin Y, Wang X, Zhu M et al. Expansion of CD26 positive fibroblast population promotes keloid progression. *Exp Cell Res* 2017; 356: 104–113.
- 7 Thielitz A, Vetter R W, Schultze B et al. Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. *J Invest Dermatol* 2008; 128: 855–866.
- 8 Mah W, Jiang G, Olver D et al. Elevated CD26 Expression by Skin Fibroblasts Distinguishes a Profibrotic Phenotype Involved in Scar Formation Compared to Gingival Fibroblasts. *Am J Pathol* 2017; 187: 1717–1735
- 9 Rinkevich Y, Walmsley GG, Hu MS, Maan ZN, Newman AM, Drukker M, et al. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential. *Science*. 2015;348:aaa2151
10. Kikkawa F, Kajiyama H, Shibata K, et al. Dipeptidyl peptidase IV in tumor progression [ J ]. *Biochim Biophys Acta*, 2005, 1751(1): 45-51.
- 11 F. Zhuge, Y. Ni, M. Nagashimada, N. Nagata, L. Xu, N. Mukaida, et al., DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization, *Diabetes* 65 (10) (2016) 2966–2979.
- 12 Y. Sun, L. Ma, Role of dipeptidyl peptidase-4 and its inhibitor in the respiratory diseases . *Zhong nan da xue xue bao Yi xue ban, J. Cent. South Univ. Med. Sci.* 42 (1) (2017) 108–112.
- 13 T. Shiobara, K. Chibana, T. Watanabe, R. Arai, Y. Horigane, Y. Nakamura, et al., Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells, *Respir. Res.* 17 (2016) 28.
- 14 S. Steven, K. Jurk, M. Kopp, S. Kroller-Schon, Y. Mikhed, K. Schwierczek, S. Roohani, F. Kashani, M. Oelze, T. Klein, S. Tokalov, S. Danckwardt, S. Strand, P. Wenzel, T. Munzel, A. Daiber, Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice, *Br. J. Pharmacol.* 174 (2017) 1620–1632.
- 15 Toshio Suzuki, Yuji Tada, Santhi Gladson Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition *Respiratory Research* (2017) 18:177
- 16 Manar A. Nader Inhibition of airway inflammation and remodeling by sitagliptin in murine chronic asthma *International Immunopharmacology* 29 (2015) 761–769



- 17 Yang Liu, Yongchao Qi Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix *International Immunopharmacology* 87 (2020) 106774
- 18 Xiuwu Liu, Tao Zhang, Chengcai Zhang Sitagliptin Inhibits Extracellular Matrix Accumulation and Proliferation in Lung Fibroblasts *Med Sci Monit*, 2020; 26: e922644
- 19 Manar G. Helal Saxagliptin mitigates airway inflammation in a mouse model of acute asthma via modulation of NF- $\kappa$ B and TLR4 *Life Sciences* 239 (2019) 117017
- 20 Jian Xu Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension *Laboratory Investigation* (2018) 98:1333–1346
- 21 Shota Hodono Ethyl Pyruvate Improves Pulmonary Function in Mice with Bleomycin-induced Lung Injury as Monitored with Hyperpolarized  $^{129}\text{Xe}$  MR Imaging *Magn Reson Med Sci* 2018; 17; 331–337
- 22 Enomoto, T., Usuki, J., Azuma, A., Nakagawa, T., and Kudoh, S. (2003) Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. *Chest* 123, 2007–2011.
- 23 D.C. Rockey, Current and future anti-fibrotic therapies for chronic liver disease, *Clin. Liver Dis.* 12 (2008) 939e962 (xi).
- 24 V. Hernandez-Gea, S.L. Friedman, Pathogenesis of liver fibrosis, *Annu. Rev. Pathol.* 6 (2011) 425e456.
- 25 J.A. Fallowfield, Therapeutic targets in liver fibrosis, *Am. J. Physiol. Gastrointest. Liver Physiol.* 300 (2011) G709eG715.
- 26 C. Yin, K.J. Evason, K. Asahina, D.Y. Stainier, Hepatic stellate cells in liver development, regeneration, and cancer, *J. Clin. Invest.* 123 (2013) 1902e1910.
- 27 L. Cordero-Espinoza, M. Huch, The balancing act of the liver: tissue regeneration versus fibrosis, *J. Clin. Invest.* 128 (2018) 85e96.
- 28 T. Fujita, S. Narumiya, Roles of hepatic stellate cells in liver inflammation: a new perspective, *Inflamm. Regen.* 36 (2016) 1.
- 29 N.C. Leite, G.F. Salles, A.L. Araujo, C.A. Villela-Nogueira, C.R. Cardoso, Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus, *Liver Int.* 29 (2009) 113e119.
- 30 Hanyan Zhang , Dandan Sun, Guanzhen Wang Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell *Biochemical and Biophysical Research Communications* 511 (2019) 387e393
- 31 Yuichiro Amano a, Shuntarou Tsuchiya, Mayumi Imai Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis *Biochemical and Biophysical Research Communications* 497 (2018) 207e213
- 32 Daisuke Kaya, Kosuke Kaji , Yuki Tsuji TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development

Mediated by Anagliptin in Diabetic Rats Cells 2019, 8, 1153

33 Teruo Jojima, Takanori Tomotsune, Toshie Iijima Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes Diabetol Metab Syndr (2016) 8:45

34 Thomas Klein, Masato Fujii, Jan Sandel Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis Med Mol Morphol (2014) 47:137–149

35 Yara M. Aboulmagda, Alshaymaa A.Z. El-Bahya, Esther T. Menze Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats European Journal of Pharmacology 881 (2020) 173224

36 Xiaoyu Wang, Michael Hausding, Shi Yen Weng Gliptins suppress inflammatory macrophage activation to mitigate inflammation, fibrosis, oxidative stress and vascular dysfunction in models of non-alcoholic steatohepatitis and liver fibrosis Antioxidants and Redox Signaling DOI: 10.1089/ars.2016.6953

37 Takahiro Ozutsumi, Tadashi Namisaki, Naotaka Shimozato Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis Int. J. Mol. Sci. 2020, 21, 2164

38 Rania Khalila, Ahmed Shatab, Eman M. Abd El-Kader Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38 $\alpha$ , and NF- $\kappa$ B signaling. Toxicology and Applied Pharmacology 407 (2020) 115246

39 Fu-Shun Yen, James, Cheng-Chung Wei, Hei Tung Yip Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan Hepatology International (2021) 15:179–190

40 Jeffrey Cui, Len Philo, Phirum Nguyen Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial Journal of Hepatology 2016 vol. 65 j 369–376

41 Kosuke Kaji, Hitoshi Yoshiji, Yasuhide Ikenaka Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats J Gastroenterol DOI 10.1007/s00535-013-0783-4

42 Mark M. Smits, Lennart Tonneijck, Marcel H. A. Muskiet Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial Diabetologia DOI 10.1007/s00125-016-4100-7

43 Naotaka Shimozato, Tadashi Namisaki, Kosuke Kaji Combined effect of a farnesoid X receptor agonist and dipeptidyl

peptidase-4 inhibitor on hepatic fibrosis *Hepatology Research* 2019; 49: 1147–1161

44 Samia Salem Sokara, Magda El-Sayed El-Sayada, Mai El-Sayed Ghoneim Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats *Biomedicine & Pharmacotherapy* 89 (2017) 98–107

45 Shahinul Alam, Jhumur Ghosh, Golam Mustafa Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial *Hepatic Medicine: Evidence and Research* 2018;10 23–31

46 Takumi Onoyama, Masahiko Koda, Toshiaki Okamoto Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice *Molecular Medicine Reports* 12: 6895-6902, 2015

47 Tisha R Joy, Charles A McKenzie, Rommel G Tirona Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial *World J Gastroenterol* 2017 January 7; 23(1): 141-150

48 Yun-A. Jung<sup>1</sup>, Yeon-Kyung Choi<sup>b</sup>, Gwon-Soo Jung Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis diabetes research and clinical practice 105 (2014)47–57

49 Kawaguchi, T., Nakano, D., Koga, H., Torimura, T., 2019. Effects of a DPP4 inhibitor on progression of NASH-related HCC and the p62/Keap1/Nrf2-pentose phosphate pathway in a mouse model. *Liver Cancer* 8, 346–359.

50 Seghieri, M., Christensen, A.S., Andersen, A., Solini, A., Knop, F.K., Vilsbøll, T., 2018. Future perspectives on GLP-1 receptor agonists and GLP-1/glucagon receptor coagonists in the treatment of NAFLD. *Front. Endocrinol.* 9, 649.

51 Yuki Tanaka, Shinji Kume Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury *Biochemical and Biophysical Research Communications* 470 (2016) 539e545

52 Anna-Lena Mayer The DPP4 inhibitor linagliptin ameliorates renal injury and accelerated resolution in a rat model of crescentic nephritis

53 Mentlein, R., 1999. Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. *Regul. Pept.* 85, 9–24.

54 Takahiro Uchida, Takashi Oda, Hidehito Matsubara Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis *RENAL FAILURE*, 2017 VOL. 39, NO. 1, 340–349

55 Jung Beom Seo, Yeon-Kyung Choi, Hye-In Woo Gemigliptin Attenuates Renal Fibrosis Through DownRegulation of the NLRP3 Inflammasome *Diabetes Metab J* 2019;43:830-839

56 Mayer, A., Scheitacker, I., Ebert, N., Klein, T., Amann, K., & Daniel, C The DPP4 inhibitor linagliptin ameliorated renal injury and accelerated resolution in a rat model of crescentic nephritis. *British Journal of Pharmacology*, 178(4), 878–895.

57 Keizo Kanasaki, Sen Shi, Megumi Kanasaki Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen *Diabetes*

2014;63:2120–2131

58 Muralikrishna Gangadharan Komala, Simon Gross, Amgad Zaky, Carol Pollock Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGF $\beta$  through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin PLOS ONE | DOI:10.1371/journal.pone.0141143

59 Oleg Tsuprykov, Ryotaro Ando, Christoph Reichetzedder The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy Kidney International (2016) 89(5), 1049–1061.

60 Masako Uchii, Naoya Kimoto, Mariko Sakai Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats European Journal of Pharmacology 783 (2016) 56–63

61 MURALIKRISHNA GANGADHARAN KOMALA, SIMON GROSS, AMGAD ZAKY Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes Nephrology 21 (2016) 423–431

62 Wei Jing Liu, Shu Hua Xie, Yu Ning Liu Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats The Journal Of Pharmacology And Experimental Therapeutics 340:248–255, 2012

63 Cristina Mega, Edite Teixeira de Lemos, Helena Vala Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat) Experimental Diabetes Research Volume 2011, Article ID 162092, 12 pages

64 Dongdong Wang, Guanying Zhang, Xiao Chen Sitagliptin ameliorates diabetic nephropathy by blocking TGF- $\beta$ 1/Smad signaling pathway INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 41: 2784-2792, 2018

65 Esther Civantos, Enrique Bosch, Elisa Ramirez Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2017:10 207–222

66 Jian Xu, Jingjing Wang, Yusheng Cheng Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats BioMed Research International Volume 2018, Article ID 1864107, 14 pages

67 LUXIN LI, XU LIAN, ZHILONG WANG The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice via inhibiting the TGF- $\beta$ /Smad signal pathway Pharmazie 74: 239-242 (2019)

68 Md. Ashraful Alam, Mohammed Riaz Hasan Chowdhury DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats Diabetol Metab Syndr (2015) 7:107

- 69 Chor Ho Joa,Sua Kima,Joon-Sung Parkb Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy Kidney Blood Press Res 2018;43:987-999
- 70 Mentlein R. Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept 1999;85:9–24
- 71 Ghersi G, Dong H, Goldstein LA, et al. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem 2002;277:29231–29241
- 72 Broxmeyer HE, Hoggatt J, O’Leary HA, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med 2012;18:1786–1796
- 73 Arscott WT, LaBauve AE, May V, Wesley UV. Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation. Oncogene 2009;28:479–491
- 74 Pettitt, D. J., Saad, M. F., Bennett, P. H., Nelson, R. G., and Knowler, W. C. (1990) Familial predisposition to renal disease in two generations of Pima Indians with type-2 (non-insulin dependent) diabetes mellitus. Diabetologia 33, 438–443.
- 75 Michel, J.-B., Lattion, A.-L., Salzmann, J.-L., Cerol, M. L., Philippe, M., Camilleri, J.-P., and Corvol, P. (1988) Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction. Circ. Res. 62, 641–650.
- 76 Xiaowei Zhang, Zhiwei Zhang, Yajuan Yang Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits Cardiovasc Diabetol (2018) 17:160
- 77 Annayya R. Aroor, James R. Sowers, Shawn B. Bender Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats Endocrinology, July 2013, 154(7):2501–2513
- 78 Annayya R. Aroor, Javad Habibi, Hemanth Kumar Kandikattu Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice Cardiovasc Diabetol (2017) 16:61
- 79 Hiroyuki Hirakawa, Hirofumi Zempo, Masahito Ogawa A DPP-4 Inhibitor Suppresses Fibrosis and Inflammation on Experimental Autoimmune Myocarditis in Mice PLOS ONE | DOI:10.1371/journal.pone.0119360
- 80 Li-Hui Zhang, Xue-Fen Pang, Feng Bai Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart Cardiovasc Drugs Ther (2015) 29:243–255
- 81 Tazuru Igarashi, Shinichi Niwano, Hiroe Niwano Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation Heart and Vessels <https://doi.org/10.1007/s00380-018-1170-0>

- 82 Xian-wei WANG, Fen-xi ZHANG, Fen YANG Effects of linagliptin and liraglutide on glucose and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in Vitro *Acta Pharmacologica Sinica* (2016) 37: 1349–1358
- 83 Jessica A. Hiemstra, BS; Dong I. Lee, PhD; Khalid Chakir Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic-Banded Mini-Swine *Journal of the American Heart Association* DOI: 10.1161/JAHA.116.003277
- 84 Junichi Ikeda, Naoya Kimoto, Tetsuya Kitayama Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats *Journal of Pharmacological Sciences* 132 (2016) 65e70
- 85 Scott M. Brown, Cassandra E. Smith, Alex I. Meuth Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Ameliorates Angiotensin II–Induced Cardiac Diastolic Dysfunction in Male Mice *Endocrinology*, October 2017, 158(10):3592–3604
- 86 Ahmed A.M. Abdel-Hamida, Alaa El-Din L. Firgany Impact of vildagliptin on vascular and fibrotic remodeling of myocardium in experimental diabetic cardiomyopathy *Acta Histochemica* 122 (2020) 151499
- 87 Ayako Takahashi, Masanori Asakura, Shin Ito Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice *Am J Physiol Heart Circ Physiol* 304: H1361–H1369, 2013
- 88 Nattayaporn Apaijai, Tharnwimol Inthachai, Suree Lekawanvijit Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction *Journal of Endocrinology* (2016) 229, 245–258
- 89 Tharnwimol Inthachai, Suree Lekawanvijit, Sirinart Kumfu Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodeling in rats with chronic myocardial infarction *Exp Physiol* 100.6 (2015) pp 667–679
- 90 Toru Miyoshi, Kazufumi Nakamura, Masashi Yoshida Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats *Cardiovascular Diabetology* 2014, 13:43
- 91 Picatoste B, Ramírez E, Caro-Vadillo A, Iborra C, Egido J, et al. (2013) Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms. *PLoS ONE* 8(10): e78330. doi:10.1371/journal.pone.0078330
- 92 Grazia Esposito, Donato Cappetta, Rosa Russo Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction *British Journal of Pharmacology* (2017) 174 4070–4086
- 93 Kim Alexander Connelly, Yanling Zhang, Andrew Advani DPP-4 Inhibition Attenuates Cardiac Dysfunction and Adverse Remodeling Following Myocardial Infarction in Rats with Experimental Diabetes *Cardiovascular Therapeutics* 31 (2013) 259–267

- 94 M. Lenski, A. Kazakov, N. Marx Effects of DPP-4 inhibition on cardiac metabolism and function in mice *Journal of Molecular and Cellular Cardiology* 51 (2011) 906–918
- 95 Md. Ashraful Alam, Mohammed Riaz Hasan Chowdhury, Preeti Jain DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) Rats *Diabetol Metab Syndr* (2015) 7:107
- 96 Nouf M Al-Rasheed, Nawal M Al-Rasheed, Iman H Hasan Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats *Drug Design, Development and Therapy* 2016:10 2095–2107
- 97 Nouf T. Al-Damry, Hala A. Attiaa, Nawal M. Al-Rasheed Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3 $\beta$  and p38 $\alpha$ /MAPK in a rat model of diabetic cardiomyopathy *Biomedicine & Pharmacotherapy* 107 (2018) 347–358
- 98 Yu-Sheng Liu, Zhi-Wei Huang, Lin Wang Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats *Journal of Pharmacological Sciences* 127 (2015) 260e274
- 99 Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. *Pharmacol Ther.* 2008;120:292–316.
- 100 Namsolleck P, Recarti C, Foulquier S, Steckelings UM, Unger T. AT2 receptor and tissue injury: therapeutic implications. *Curr Hypertens Res.* 2014;16:416–26.
- 101 Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. *Circulation* 117: 2340 –2350, 2008.
- 102 Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen YT, Shannon RP. Glucagon-like peptide-1 increases myocardial glucose uptake via p38 $\alpha$  MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. *Circ Heart Fail* 3:512–521, 2010.
- 103 Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagonlike peptide 1 can directly protect the heart against ischemia/reperfusion injury. *Diabetes* 54: 146 –151, 2005.
- 104 Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. *Endocrinology* 144: 1444 –1455, 2003.
- 105 Michishige Terasaki, Munenori Hiromura, Yusaku Mori Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in

- 106 Nga N. Ta, MS, Corinne A. Schuyler, Yanchun Li DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E - Deficient Mice J Cardiovasc Pharmacol Volume 58, Number 2, August 2011
- 107 Tomoya Mita, Naoto Katakami, Hidenori Yoshii Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Diabetes Care 2016;39:139 – 148 | DOI: 10.2337/dc15-0781
- 108 Zubair Shah, Thomas Kampfrath, Jeffrey A. DeWille Chronic DPP-4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis Circulation. 2011 November 22; 124(21): 2338 – 2349. doi:10.1161/Circulationaha.111.041418.
- 109 Tsutomu Hirano, Satoko Yamashita, Masaki Takahashi Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits Metabolism Clinical And Experimental 65 (2016) 893 – 903
- 110 Hwan-Jin Hwang, Hye Soo Chung, Tae Woo Jung The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms Molecular and Cellular Endocrinology 405 (2015) 25 – 34
- 111 Camila Manrique, Javad Habibi, Annayya R. Aroor Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice Cardiovasc Diabetol (2016) 15:94
- 112 Haoran Wang, Yue Li, Xiaoliang Zhang DPP-4 Inhibitor Linagliptin Ameliorates Oxidized LDL-Induced THP-1 Macrophage Foam Cell Formation and Inflammation Drug Design, Development and Therapy 2020;14 3929 – 3940
- 113 Hotimah Masdan Salim, Daiju Fukuda, Yasutomi Higashikuni Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice Vascular Pharmacology 79 (2016) 16 – 23
- 114 Shuhei Nishida, Takeshi Matsumura, Takafumi Senokuchi Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions Biochemical and Biophysical Research Communications 524 (2020) 8e15
- 115 Stefanie A. de Boer, Hiddo J. L. Heerspink, Luis E. Juárez Orozco Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE) Diabetes Obes Metab. 2017;19:1147 – 1154.



- 116 Kunduziayi Aini, Daiju Fukuda, Kimie Tanaka Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice *Int Heart J* 2019; 60: 1421-1429
- 117 Michishige Terasaki, Masaharu Nagashima, Takuya Watanabe Effects of PKF275-055, a dipeptidyl peptidase - 4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E - null mice *METABOLISM CLINICAL AND EXPERIMENTAL* 61 (2012) 974 - 977
- 118 Rehab Werida, Mahmoud Kabel, Gamal Omran Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease diabetes research and clinical practice 170 (2020) 108473
- 119 Bo Lia, Yan-Rong Luo, Feng Tian Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes *Atherosclerosis* 300 (2020) 10 - 18
- 120 F. Vittone, A. Liberman, D. Vasic Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe<sup>-/-</sup> mice *Diabetologia* (2012) 55:2267 - 2275 DOI 10.1007/s00125-012-2582-5
- 121 Tomoya Mita, Naoto Katakami, Toshihiko Shiraiwa Dose-Dependent Effect of Sitagliptin on Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Post Hoc Analysis *Diabetes Ther* (2017) 8:1135 - 1146 DOI 10.1007/s13300-017-0309-9
- 122 Tsuyoshi Nozue, Kazuki Fukui, Yutaka Koyama Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes-A serial integrated backscatter-intravascular ultrasound study *Am J Cardiovasc Dis* 2016;6(4):153-162
- 123 Xiaojie Liu, Tao Mei, Wei Chen Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients Mediators of Inflammation Volume 2017, Article ID 5032708, 6 pages <https://doi.org/10.1155/2017/5032708>
- 124 Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. *Exp Physiol* 2005;90: 449-55.
- 125 Shirwany NA, Zou MH. Arterial stiffness: a brief review. *Acta Pharmacol Sin* 2010;31:1267-76.
- 126 Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. *J Atheroscler Thromb* 2003;10:267-74.
- 127 Arteaga-Solis E, Gayraud B, Ramirez F. Elastic and collagenous networks in vascular diseases. *Cell Struct Funct* 2000;25:69-72.
- 128 Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. *Biomed Pharmacother* 2003;57:195-202.
- 129 Arribas SM, Hinek A, Gonzalez MC. Elastic fibres and vascular structure in hypertension. *Pharmacol Ther*

2006;111:771–91.

130 Tao-Hua Lan, Xiong-Qing Huang, Hong-Mei Tan Vascular fibrosis in atherosclerosis , Cardiovascular Pathology (2013), <http://dx.doi.org/10.1016/j.carpath.2013.01.003>

131 Y. Hirata, H. Kurobe, C. Nishio, K. Tanaka, D. Fukuda, E. Uematsu, S. Nishimoto, T. Soeki, N. Harada, H. Sakaue, T. Kitagawa, M. Shimabukuro, Y. Nakaya, M. Sata, Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury, Eur. J. Pharmacol. 699 (1 – 3) (2013) 106 – 111.

132 Terasaki M, Nagashima M, Nohtomi K, et al. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin' s actions in nondiabetic and diabetic apolipoprotein E-null mice. PLOS ONE 2013; 8: e70933.

133R. Ross, Atherosclerosis d an inflammatory disease, N. Engl. J. Med. 340(1999) 115e126, <https://doi.org/10.1056/NEJM199901143400207>.

134 D. Tugal, X. Liao, M.K. Jain, Transcriptional control of macrophage polarization, Arterioscler. Thromb. Vasc. Biol. 33 (2013) 1135e1144, <https://doi.org/10.1161/ATVBAHA.113.301453>.

135 G. Chinetti-Gbaguidi, M. Baron, M.A. Bouhrel, et al., Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPAR $\gamma$  and LXRA pathways, Circ. Res. 108 (2011) 985e995, <https://doi.org/10.1161/CIRCRESAHA.110.233775>.

136 K.J. Moore, F.J. Sheedy, F.A. Fisher, Macrophages in atherosclerosis: a dynamic balance, Nat. Rev. Immunol. 13 (2013) 709e721, <https://doi.org/10.1038/nri3520>.

137 F. Zhuge, Y. Ni, M. Nagashimada, et al., DPP-4 inhibition by linagliptin attenuates obesity-related inflammation and insulin resistance by regulating M1/M2 macrophage polarization, Diabetes 65 (2016) 2966e2979, <https://doi.org/10.2337/db16-0317>.

138 Nagai T, Doi S, Nakashima A, Irifuku T, Sasaki K, Ueno T, et al. (2016) Linagliptin Ameliorates Methylglyoxal-Induced Peritoneal Fibrosis in Mice. PLoS ONE 11(8): e0160993. doi:10.1371/journal.pone.0160993

139 Fang Wang, Zhi-Fen Zhang, Yi-Ran He Effects of dipeptidyl peptidase-4 inhibitors on transforming growth factor- $\beta$ 1 signal transduction pathways in the ovarian fibrosis of polycystic ovary syndrome rats J. Obstet. Gynaecol. Res. Vol. 45, No. 3: 600–608, March 2019

140 Samuel T. Olatunbosun Chronic incretin-based therapy in cystic fibrosis-related diabetes: A tale of 3 patients treated with sitagliptin for over 5 years Journal of Cystic Fibrosis March 10, 2021;16:23

141 Yi-Chen Li, Pei-Hsun Sung, Yao-Hsu Yang Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis communications biology | <https://doi.org/10.1038/s42003-021-01652-x>

- 142 Alina Soare, Hermina A. Györfi, Alexandru E. Matei Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis Arthritis & Rheumatology Vol. 72, No. 1, January 2020, pp 137–149
- 143 Yan Li, Julei Zhang, Qin Zhou Linagliptin inhibits high glucose-induced transdifferentiation of hypertrophic scar-derived fibroblasts to myofibroblasts via IGF/Akt/mTOR signalling pathway Experimental Dermatology. 2019;28:19–27
- 144 Ana Patrícia Marques, Janete Cunha-Santos, Helena Leal Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice BBA - General Subjects 1862 (2018) 403–413
- 145 Sherif S. Farag, Mohammad Abu Zaid, Jennifer E. Schwartz, Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease N Engl J Med 2021; 384:11-19 DOI: 10.1056/NEJMoa2027372
- 146 Hirotsugu Suwanai, Ryo Watanabe, Munemori Sato Dipeptidyl Peptidase-4 Inhibitor Reduces the Risk of Developing Hypertrophic Scars and Keloids following Median Sternotomy in Diabetic Patients: A Nationwide Retrospective Cohort Study Using the National Database of Health Insurance Claims of Japan Plastic and Reconstructive Surgery DOI: 10.1097/PRS.0000000000006904
- 147 Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55–72.
- 148 Long M, Cai L, Li W, et al. DPP-4 inhibitors improve diabetic wound healing via direct and indirect promotion of epithelial-mesenchymal transition and reduction of scarring. Diabetes 2018;67:518–531.
- 149 Hu MS, Longaker MT. Dipeptidyl peptidase-4, wound healing, scarring, and fibrosis. Plast Reconstr Surg. 2016;138:1026–1031.
- 150 Thomas A Wynn, Thirumalai R Ramalingam. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. nature medicine Volume 18 | Number 7 | July 2012

